BioRegenx, Inc. (BRGX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioRegenx, Inc. (BRGX) with AI Score 61/100 (Hold). BioRegenx, Inc. develops and sells medical test equipment and nutritional products, focusing on microvascular health. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026BioRegenx, Inc. (BRGX) Healthcare & Pipeline Overview
BioRegenx, Inc. focuses on developing and marketing medical test equipment and science-based nutritional products, including the Endocalyx Pro supplement and GlycoCheck software, targeting microvascular health. The company leverages a direct selling model and operates in the competitive healthcare information services sector.
Investment Thesis
BioRegenx, Inc. presents a high-risk, high-reward investment profile due to its focus on innovative health technologies and nutritional products. The company's success hinges on the market adoption of its key products, including Endocalyx Pro and GlycoCheck software. With a market capitalization of $0.01 billion and a negative P/E ratio of -0.65, the company's financial performance is currently challenged, as reflected in its -981.0% profit margin. Future growth depends on successful commercialization of its TruScan.Ai and VitalWellness platforms, as well as expansion of its direct selling network. Investors should closely monitor the company's ability to improve profitability and manage its high beta of -3.57, indicating significant volatility relative to the market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -0.65 reflects current unprofitability, requiring careful monitoring of future earnings potential.
- Gross Margin of 159.6% suggests strong pricing power on products, but this is offset by high operating expenses.
- Profit Margin of -981.0% highlights significant challenges in achieving profitability, requiring substantial operational improvements.
- Beta of -3.57 indicates high volatility and a negative correlation with the market, suggesting potential for diversification benefits but also increased risk.
Competitors & Peers
Strengths
- Innovative product portfolio targeting microvascular health.
- Direct selling model provides direct access to key customer segments.
- Development of AI-driven health monitoring technologies.
- Proprietary formulations for nutritional supplements.
Weaknesses
- Negative profitability and high operating expenses.
- Small market capitalization and limited financial resources.
- High beta indicates significant stock price volatility.
- Reliance on a small number of key products.
Catalysts
- Upcoming: Launch of TruScan.Ai mobile app and website, expected within the next 12-18 months.
- Ongoing: Expansion of direct selling network to reach more health professionals and research organizations.
- Ongoing: Development and integration of DocSun AI Engine into existing products.
- Ongoing: Pursuit of strategic partnerships with key opinion leaders and medical institutions.
- Ongoing: Efforts to increase awareness and adoption of GlycoCheck software.
Risks
- Potential: Competition from larger, more established healthcare companies.
- Potential: Regulatory challenges and changing healthcare policies.
- Potential: Product liability risks associated with medical devices and supplements.
- Ongoing: Negative profitability and high operating expenses.
- Ongoing: Limited financial resources and high stock price volatility.
Growth Opportunities
- Expansion of TruScan.Ai and VitalWellness Platforms: The development and successful launch of the TruScan.Ai mobile app and VitalWellness app represent a significant growth opportunity for BioRegenx. These platforms, which integrate health indicators and DNA/epigenetics data, could attract a large user base seeking personalized health insights. The market for personalized medicine is projected to reach $2.4 billion by 2028, offering a substantial addressable market for BioRegenx. Timeline for full commercial launch is expected within the next 12-18 months.
- Increased Adoption of GlycoCheck Software: GlycoCheck software, which assesses microvascular health, has the potential to become a standard tool for healthcare professionals. As awareness of microvascular health grows, demand for GlycoCheck could increase significantly. The global microcirculation market is projected to reach $1.5 billion by 2027. BioRegenx can capitalize on this trend by expanding its marketing efforts and partnering with medical institutions.
- Strategic Partnerships with Health Professionals and Research Organizations: BioRegenx's direct selling model, which targets health professionals and research organizations, provides a strong foundation for growth. By forming strategic partnerships with key opinion leaders and institutions, the company can increase its credibility and reach. These partnerships can also facilitate clinical trials and research studies, further validating the efficacy of BioRegenx's products.
- International Market Expansion: BioRegenx currently operates internationally, but there is significant potential to expand its presence in key markets. By tailoring its products and marketing strategies to specific regions, the company can tap into new customer segments and revenue streams. Emerging markets, in particular, offer significant growth opportunities due to increasing healthcare spending and a growing awareness of preventive care.
- Integration of DocSun AI Engine: The DocSun AI Engine, which integrates advanced ballistocardiography and photoplethysmography, represents a cutting-edge technology that could differentiate BioRegenx from its competitors. By integrating this technology into its existing products and platforms, the company can offer more comprehensive and personalized health assessments. The market for AI in healthcare is projected to reach $34 billion by 2025, providing a significant growth opportunity for BioRegenx.
Opportunities
- Expansion of TruScan.Ai and VitalWellness platforms.
- Increased adoption of GlycoCheck software.
- Strategic partnerships with health professionals and research organizations.
- International market expansion.
Threats
- Competition from larger, more established healthcare companies.
- Regulatory challenges and changing healthcare policies.
- Product liability risks associated with medical devices and supplements.
- Economic downturns impacting consumer spending on health and wellness products.
Competitive Advantages
- Proprietary formulations for nutritional supplements like Endocalyx Pro.
- GlycoCheck software offers a unique method for assessing microvascular health.
- Direct selling model fosters strong relationships with health professionals.
- Development of AI-driven health monitoring technologies like DocSun.
About BRGX
BioRegenx, Inc., headquartered in Chattanooga, Tennessee, is a healthcare company specializing in the development, manufacture, and sale of medical test equipment and science-based nutritional products. The company's flagship product is Endocalyx Pro, a dietary supplement designed to support microvascular capillary health. In addition to Endocalyx Pro, BioRegenx offers a range of other supplements under the MyBodyRx brand. The company also provides GlycoCheck software, a tool used to assess microvascular health. BioRegenx offers a variety of health and wellness devices, including pulsed electro-magnetic field devices, StimaWELL, and ReLounge, an electronic muscle stimulation therapy device. The company also markets hydrogen water products. BioRegenx is actively developing TruScan.Ai, a mobile app and website designed to integrate various health indicators, and VitalWellness, an app that merges its DNA and epigenetics platform. Furthermore, the company operates a social media content management platform, including an interactive search engine. BioRegenx also provides the DocSun Artificial Intelligence (AI) Engine, which integrates advanced ballistocardiography to detect an individual's heartbeat without touch, photoplethysmography to track blood flow, and distributes wellness devices. The company distributes its products through a direct selling channel, targeting health professionals and research organizations both in the United States and internationally.
What They Do
- Develops and manufactures medical test equipment.
- Sells science-based nutritional products.
- Offers Endocalyx Pro, a dietary supplement for microvascular health.
- Provides GlycoCheck software for assessing microvascular health.
- Markets health and wellness devices, including pulsed electro-magnetic field devices.
- Develops TruScan.Ai and VitalWellness apps for personalized health insights.
- Operates a social media content management platform.
- Provides the DocSun Artificial Intelligence (AI) Engine for advanced health monitoring.
Business Model
- Direct sales to health professionals and research organizations.
- Sales of dietary supplements under the MyBodyRx brand.
- Licensing of GlycoCheck software.
- Sales of health and wellness devices.
- Potential future revenue from TruScan.Ai and VitalWellness apps.
Industry Context
BioRegenx, Inc. operates within the healthcare information services industry, a sector characterized by rapid technological advancements and increasing demand for personalized health solutions. The market is driven by trends such as the growing adoption of telehealth, the rise of wearable health devices, and the increasing focus on preventive care. BioRegenx competes with companies like ANAV, CHDHF, CREVF, DTC, and GLLDF, all vying for market share in the health and wellness space. The company's success depends on its ability to differentiate its products and effectively target its niche market of health professionals and research organizations.
Key Customers
- Health professionals (doctors, nurses, etc.)
- Research organizations (universities, hospitals, etc.)
- Individual consumers seeking health and wellness products.
Financials
Chart & Info
BioRegenx, Inc. (BRGX) stock price: Price data unavailable
Latest News
No recent news available for BRGX.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BRGX.
Price Targets
Wall Street price target analysis for BRGX.
MoonshotScore
What does this score mean?
The MoonshotScore rates BRGX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: William Resides
CEO
William Resides serves as the CEO of BioRegenx, Inc. His background includes experience in managing small teams and guiding the strategic direction of the company. He is responsible for overseeing the development, manufacturing, and sales of medical test equipment and nutritional products. His leadership is focused on expanding the company's reach through direct selling channels and strategic partnerships.
Track Record: Under William Resides' leadership, BioRegenx has focused on developing and marketing innovative products like Endocalyx Pro and GlycoCheck. A key achievement has been the development of the TruScan.Ai and VitalWellness platforms, aimed at providing personalized health insights. The company has also expanded its product line to include health and wellness devices and hydrogen water products.
BRGX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BioRegenx may not meet the minimum financial standards required for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, minimal assets, and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries significant risk due to the potential for fraud, manipulation, and lack of transparency. These companies are not required to meet specific listing requirements, which increases the risk for investors compared to companies listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in BioRegenx.
- Low trading volume and wide bid-ask spreads can lead to price volatility and difficulty in executing trades.
- The OTC Other tier designation indicates a higher risk of fraud and manipulation.
- The company's small market capitalization and limited financial resources increase the risk of business failure.
- Dependence on a small number of key products makes the company vulnerable to market changes and competition.
- Verify the availability of audited financial statements.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Research the company's regulatory compliance and legal history.
- Monitor trading volume and bid-ask spreads to assess liquidity.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Development of innovative products like Endocalyx Pro and GlycoCheck.
- Direct selling model targeting health professionals and research organizations.
- Efforts to develop AI-driven health monitoring technologies.
- International operations indicate some level of market reach.
- Company has been in operation for several years.
What Investors Ask About BioRegenx, Inc. (BRGX)
What does BioRegenx, Inc. do?
BioRegenx, Inc. is a healthcare company that develops, manufactures, and sells medical test equipment and science-based nutritional products. Its primary focus is on microvascular health, with key products including Endocalyx Pro, a dietary supplement, and GlycoCheck software, a tool for assessing microvascular function. The company also offers a range of health and wellness devices and is developing AI-driven health monitoring technologies. BioRegenx distributes its products through a direct selling channel, targeting health professionals and research organizations both in the United States and internationally.
What do analysts say about BRGX stock?
As of 2026-03-15, there is no available analyst coverage for BioRegenx, Inc. (BRGX). Given its micro-cap status and OTC listing, the company may not be widely followed by analysts. Investors should conduct their own thorough research and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key metrics to monitor include revenue growth, profitability, and cash flow.
What are the main risks for BRGX?
BioRegenx, Inc. faces several key risks, including intense competition from larger healthcare companies, regulatory challenges related to medical devices and supplements, and product liability risks. The company's negative profitability and high operating expenses pose a significant financial risk. Additionally, its small market capitalization and limited financial resources make it vulnerable to market fluctuations and economic downturns. The OTC listing and lack of financial disclosure also increase the risk for investors.
How does BioRegenx, Inc. generate revenue in the healthcare sector?
BioRegenx, Inc. generates revenue through several streams within the healthcare sector. Primarily, it derives income from the direct sales of its nutritional supplements, such as Endocalyx Pro, and its GlycoCheck software, which is used for microvascular assessment. Additionally, the company generates revenue from the sale of various health and wellness devices. Future revenue streams are anticipated from the commercialization of its TruScan.Ai and VitalWellness platforms, which aim to provide personalized health insights based on integrated health data.
What is BioRegenx, Inc.'s strategy for protecting its intellectual property?
BioRegenx, Inc.'s strategy for protecting its intellectual property likely involves a combination of methods, including patents, trademarks, and trade secrets. While specific details of their IP protection strategy are not provided, the company likely seeks patent protection for its innovative technologies, such as the DocSun AI Engine and unique formulations of its nutritional supplements. Trademarks are likely used to protect its brand names, such as Endocalyx Pro and MyBodyRx. Additionally, the company may rely on trade secrets to protect proprietary manufacturing processes and formulations.
What are the key factors to evaluate for BRGX?
BioRegenx, Inc. (BRGX) currently holds an AI score of 61/100, indicating moderate score. Key strength: Innovative product portfolio targeting microvascular health.. Primary risk to monitor: Potential: Competition from larger, more established healthcare companies.. This is not financial advice.
How frequently does BRGX data refresh on this page?
BRGX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BRGX's recent stock price performance?
Recent price movement in BioRegenx, Inc. (BRGX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative product portfolio targeting microvascular health.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data based on available information and may not be fully comprehensive.
- AI analysis pending for BRGX, limiting insight.